title: Olanzapine increases grey and white matter volumes in the caudate nucleus of patients with schizophrenia.
abstract: There are inconsistent reports regarding the caudate nucleus volume in patients with schizophrenia compared with healthy subjects. The reason for this is that neuroleptic medication may affect the volume of the caudate nucleus in schizophrenic patients. To clarify which antipsychotic medication changes the volume of the caudate nucleus in patients with schizophrenia, we measured the volumes of grey and white matter in the caudate nucleus of schizophrenic patients. Ten patients with schizophrenia were examined twice by magnetic resonance imaging (MRI) to measure the grey and white matter volumes in the caudate nucleus. After the first MRI examination, all the patients were treated with olanzapine. The clinical responses were evaluated by the positive and negative rating scale. When the symptoms improved, the patients were examined by a second MRI scan. Ten healthy control subjects also underwent MRI. The schizophrenic patients had reduced volumes of grey and white matter in the caudate nucleus compared to the healthy control subjects. The volumes of grey and white matter in the caudate nucleus of the schizophrenic patients increased after treatment with olanzapine. These findings suggest that treatment with olanzapine may increase the grey and white matter volumes in the caudate nucleus in patients with schizophrenia.
authors.affiliation: Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan. okugawa@takii.kmu.ac.jp
authors.forename: Gaku
authors.initials: G
authors.lastname: Okugawa
authors.forename: Kenji
authors.initials: K
authors.lastname: Nobuhara
authors.forename: Katsunori
authors.initials: K
authors.lastname: Takase
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Saito
authors.forename: Masafumi
authors.initials: M
authors.lastname: Yoshimura
authors.forename: Toshihiko
authors.initials: T
authors.lastname: Kinoshita
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use*; D001569:Benzodiazepines / Q000627:therapeutic use; D002421:Caudate Nucleus / Q000187:drug effects* / Q000473:pathology*; D005260:Female; D006801:Humans; D007091:Image Processing, Computer-Assisted / Q000379:methods; D008279:Magnetic Resonance Imaging / Q000379:methods; D008297:Male; D000077152:Olanzapine; D012559:Schizophrenia / Q000188:drug therapy* / Q000473:pathology*
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine